Patents by Inventor Bum-Tae Kim

Bum-Tae Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12103114
    Abstract: The present disclosure relates to a lead-free solder alloy composition in which a nanosized ceramic powder additive is added to a lead-free solder alloy of Sn—Cu—Bi, Sn—Ag—Bi or Sn—Ag—Cu—Bi, and a method for preparing the same.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: October 1, 2024
    Assignee: KYUNG DONG MTEC CO., LTD.
    Inventors: Heung Rak Sohn, Bum Gyu Baek, Song Hee Yim, Jun Tae Kim
  • Publication number: 20240319186
    Abstract: The present invention relates to a nanowire-based immunofluorescence kit for detecting a SARS coronavirus 2 antibody, and a use thereof, and more specifically, to a zinc oxide nanowire-based immunofluorescence kit for detecting a SARS coronavirus 2 antibody, and a use thereof, the kit comprising a step of growing nanowires on a substrate, introducing a functional group on the grown nanowires, and fixing a SARS coronavirus 2 antigen. The nanowire array of the present invention has enhanced detection sensitivity to enable more accurate diagnosis of whether or not a SARS coronavirus 2 antibody is produced.
    Type: Application
    Filed: January 11, 2022
    Publication date: September 26, 2024
    Inventors: Hong Gi KIM, Jung KIM, Bum Tae KIM, Jonghwan LEE, Nam Hoon KIM, Sung Kyun LEE
  • Patent number: 11767297
    Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
    Type: Grant
    Filed: September 7, 2022
    Date of Patent: September 26, 2023
    Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Sung Youn Chang, Hyuk Lee, Ki Young Kim, Bum Tae Kim, Sung Soo Kim, Seong Hwan Kim, Hwan Jung Lim, Jung Nyoung Heo, Sang Joon Shin, Sang Youn Park
  • Publication number: 20230220012
    Abstract: Provided are a recombinant antigen comprising a cell membrane permeation domain comprising a polypeptide of any one of SEQ ID NOs: 1 to 22 derived from human LRRC24 and a SARS-CoV-2 antigen or a fragment thereof, a vaccine composition comprising the recombinant antigen, a gene construct comprising a polynucleotide encoding the recombinant antigen, a recombinant vector comprising the gene construct, a method for producing the SARS-CoV-2 recombinant antigen, and a kit for preventing or treating SARS-CoV-2 infection comprising the vaccine composition and users' instruction thereof, wherein the antigen exhibited higher immunogenicity against SARS-CoV-2 the neutralizing antibody was better formed in actual animal experiments, excellent protective immunity was induced, and toxicity did not appear in the toxicity test.
    Type: Application
    Filed: May 13, 2021
    Publication date: July 13, 2023
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Seong Jun KIM, Chonsaeng KIM, Kyun Do KIM, Dae Gyun AHN, Young Chan KWON, Keunbon KU, Hae Soo KIM, Hye Jin SHIN, Gun Young YOON, In Su HWANG, Gi Uk JEONG, Sun Hee LEE, Mi Hwa KIM, Su Min LEE, Bum Tae KIM
  • Publication number: 20230160895
    Abstract: Provided are a composition for detecting SARS coronavirus 2, a composition for diagnosing SARS coronavirus 2 infection, a method for detecting SARS coronavirus 2, and a SARS coronavirus 2 infection diagnostic kit, wherein a receptor and an antibody that binds to SARS coronavirus 2 spike protein are used in order to detect SARS coronavirus 2 (SARS-CoV-2) or diagnose SARS coronavirus 2 infection (COVID-19).
    Type: Application
    Filed: June 18, 2021
    Publication date: May 25, 2023
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Hong Gi KIM, Jonghwan LEE, Bum Tae KIM
  • Publication number: 20230039679
    Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
    Type: Application
    Filed: September 7, 2022
    Publication date: February 9, 2023
    Inventors: Sung Youn CHANG, Hyuk LEE, Ki Young KIM, Bum Tae KIM, Sung Soo KIM, Seong Hwan KIM, Hwan Jung LIM, Jung Nyoung HEO, Sang Joon SHIN, Sang Youn PARK
  • Patent number: 11485711
    Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: November 1, 2022
    Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Sung Youn Chang, Hyuk Lee, Ki Young Kim, Bum Tae Kim, Sung Soo Kim, Seong Hwan Kim, Hwan Jung Lim, Jung Nyoung Heo, Sang Joon Shin, Sang Youn Park
  • Publication number: 20220306718
    Abstract: The present invention relates to a transmembrane domain derived from human LRRC24 protein. More specifically, the present invention relates to a transmembrane domain derived from the human LRRC24 protein (LRRC24P transmembrane domain) or a cell-penetrating peptide, and an intracellular delivery system comprising same. The transmembrane domain derived from the human LRRC24 protein of the present invention can be used to deliver cargo materials such as compounds, biomolecules, and various polymer materials into cells. Since the LRRC24P transmembrane domain of the present invention exhibits higher cell penetration efficiency compared to conventional cell-penetrating peptides and is derived from human proteins, thus avoiding side effects and immune responses caused by peptides derived from foreign proteins, it can be usefully used as an effective intracellular delivery method for compounds, biomolecules, and various polymer materials applied to the human body.
    Type: Application
    Filed: December 16, 2019
    Publication date: September 29, 2022
    Inventors: Seong Jun KIM, Kyun Do KIM, In Su HWANG, Keunbon KU, Chonsaeng KIM, Bum Tae KIM, Dae Gyun AHN, Hae Soo KIM, Young Chan KWON
  • Patent number: 11447469
    Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: September 20, 2022
    Assignees: Korea Research Institute of Chemical Technology, Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Sung Youn Chang, Hyuk Lee, Ki Young Kim, Bum Tae Kim, Sung Soo Kim, Seong Hwan Kim, Hwan Jung Lim, Jung Nyoung Heo, Sang Joon Shin, Sang Youn Park
  • Publication number: 20210047300
    Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
    Type: Application
    Filed: January 31, 2019
    Publication date: February 18, 2021
    Applicants: Korea Research Institute of Chemical Technology, Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Sung Youn CHANG, Hyuk LEE, Ki Young KIM, Bum Tae KIM, Sung Soo KIM, Seong Hwan KIM, Hwan Jung LIM, Jung Nyoung HEO, Sang Joon SHIN, Sang Youn PARK
  • Publication number: 20210047277
    Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
    Type: Application
    Filed: January 31, 2019
    Publication date: February 18, 2021
    Applicants: Korea Research Institute of Chemical Technology, Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Sung Youn CHANG, Hyuk LEE, Ki Young KIM, Bum Tae KIM, Sung Soo KIM, Seong Hwan KIM, Hwan Jung LIM, Jung Nyoung HEO, Sang Joon SHIN, Sang Youn PARK
  • Patent number: 9018233
    Abstract: The invention relates to diaminoaryl derivatives substituted by carbamate, salts thereof and a pesticidal composition containing the same, which exhibit superior pest control effects against various insect pests of insect species, in particular against moths such as the diamondback moth or Spodoptera litura.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: April 28, 2015
    Assignees: Kyung Nong Corporation, Korea Research Institute of Chemical Technology
    Inventors: Sung Youn Chang, Jung Nyoung Heo, Hyuk Lee, Hwan Jung Lim, Bum Tae Kim, Joo Kyung Kim, Jong-Kwan Kim
  • Publication number: 20150094342
    Abstract: The invention relates to diaminoaryl derivatives substituted by carbamate, salts thereof and a pesticidal composition containing the same, which exhibit superior pest control effects against various insect pests of insect species, in particular against moths such as the diamondback moth or Spodoptera litura.
    Type: Application
    Filed: May 7, 2013
    Publication date: April 2, 2015
    Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, KYUNG NONG CORPORATION
    Inventors: Sung Youn Chang, Jung Nyoung Heo, Hyuk Lee, Hwan Jung Lim, Bum Tae Kim, Joo Kyung Kim, Jong-Kwan Kim
  • Patent number: 8716326
    Abstract: The present invention relates to an amide compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition comprising the same. The inventive amide compound facilitates bone formation and inhibits bone loss, and is therefore useful for preventing and treating bone disorders such as osteoporosis, osteodystrophy, bone fracture, periodontal disease, Paget's disease, bone metastasis, and rheumatoid arthritis.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: May 6, 2014
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Jung Nyoung Heo, Bum Tae Kim, Hyuk Lee, Sung Youn Chang, Zang Hee Lee, Seong Hwan Kim, Hyun-Mo Ryoo
  • Patent number: 8227456
    Abstract: The present invention relates to a use of a specific alpha-arylmethoxyacrylate derivative, or its pharmacologically acceptable salt or solvate for preventing and treating metabolic bone diseases.
    Type: Grant
    Filed: October 14, 2009
    Date of Patent: July 24, 2012
    Assignees: Korea Research Institute of Chemical Technology, Oscotec Inc.
    Inventors: Bum Tae Kim, Yong Ki Min, Yeon Soo Lee, Jung Nyoung Heo, Hyuk Lee, No Kyun Park, Jung-Keun Kim, Se-Won Kim, Seon-Yle Ko
  • Publication number: 20120065396
    Abstract: The present invention relates to an amide compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition comprising the same. The inventive amide compound facilitates bone formation and inhibits bone loss, and is therefore useful for preventing and treating bone disorders such as osteoporosis, osteodystrophy, bone fracture, periodontal disease, Paget's disease, bone metastasis, and rheumatoid arthritis.
    Type: Application
    Filed: May 14, 2010
    Publication date: March 15, 2012
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Jung Nyoung Heo, Bum Tae Kim, Hyuk Lee, Sung Youn Chang, Zang Hee Lee, Seong Hwan Kim, Hyun-Mo Ryoo
  • Patent number: 7879835
    Abstract: The present invention relates to a use of a specific alpha-arylmethoxyacrylate derivative, or its pharmacologically acceptable salt or solvate for preventing and treating metabolic bone diseases.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: February 1, 2011
    Assignees: Korea Research Institute of Chemical Technology, Oscotec Inc.
    Inventors: Bum Tae Kim, Yong Ki Min, Yeon Soo Lee, Jung Nyoung Heo, Hyuk Lee, No Kyun Park, Jung-Keun Kim, Se-Won Kim, Seon-Yle Ko
  • Publication number: 20100256367
    Abstract: The present invention relates to a use of a specific alpha-arylmethoxyacrylate derivative, or its pharmacologically acceptable salt or solvate for preventing and treating metabolic bone diseases.
    Type: Application
    Filed: October 14, 2009
    Publication date: October 7, 2010
    Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, OSCOTEC INC.
    Inventors: Bum Tae KIM, Yong Ki Min, Yeon Soo Lee, Jung Nyoung Heo, Hyuk Lee, No Kyun Park, Jung-Keun Kim, Se-Won Kim, Seon-Yle Ko
  • Publication number: 20100144712
    Abstract: A triazole derivative of formula 1 or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof is superior to the conventional antifungal drugs in antifungal activity against a wide spectrum of pathogenic fungi, and has advantageously low toxicity.
    Type: Application
    Filed: June 12, 2008
    Publication date: June 10, 2010
    Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, CHEMON INC.
    Inventors: Bum Tae Kim, Yong Ki Min, Jung Nyoung Heo, Hyuk Lee, Sung Youn Chang, No Kyun Park, Si-Whan Song, Jung-Ja Oh
  • Publication number: 20080280901
    Abstract: The present invention relates to a use of a specific alpha-arylmethoxyacrylate derivative, or its pharmacologically acceptable salt or solvate for preventing and treating metabolic bone diseases.
    Type: Application
    Filed: June 22, 2005
    Publication date: November 13, 2008
    Applicants: Korea Research Institute of Chemical Technology, Oscotec Inc.
    Inventors: Bum Tae Kim, Yong Ki Min, Yeon Soo Lee, Jung Nyoung Heo, Hyuk Lee, No Kyun Park, Jung-Keun Kim, Se-Won Kim, Seon-Yle Ko